Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy.
Antimicrob Steward Healthc Epidemiol
; 2(1): e83, 2022.
Article
en En
| MEDLINE
| ID: mdl-36483361
ABSTRACT
Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieved clinical cure, 12% were readmitted, 12% developed hepatotoxicity, and 5% died.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Antimicrob Steward Healthc Epidemiol
Año:
2022
Tipo del documento:
Article